ImmunoGenesis
ImmunoGenesis is a Healthcare & Life Sciences startup based in the United States, most recent round Series B, 1 tracked investor.
About ImmunoGenesis
Based in the United States, ImmunoGenesis is a startup founded in 2020. Its most recent tracked round is Series B. Brouky classifies it under Healthcare & Life Sciences. Brouky records 1 investor associated with the company.
ImmunoGenesis is a clinical-stage biopharmaceutical company focused on developing immunotherapies for the treatment of cancer, specifically targeting cold tumors resistant to existing treatments. The company’s lead product, IMGS-001, is a cytotoxic immune checkpoint inhibitor designed to overcome immune resistance mechanisms in tumors.
Explore ImmunoGenesis's full profile on Brouky
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.